-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $4

Benzinga·03/28/2025 13:36:18
Listen to the news
UBS analyst Colin Bristow maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $6 to $4.